Waters Co. (NYSE:WAT) Shares Purchased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC lifted its stake in Waters Co. (NYSE:WAT - Free Report) by 88.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,814 shares of the medical instruments supplier's stock after acquiring an additional 2,256 shares during the period. Tower Research Capital LLC TRC's holdings in Waters were worth $1,786,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Aster Capital Management DIFC Ltd acquired a new stake in Waters in the fourth quarter worth approximately $28,000. Bank of Jackson Hole Trust bought a new stake in shares of Waters in the 4th quarter worth $34,000. Fortitude Family Office LLC lifted its holdings in shares of Waters by 235.7% in the fourth quarter. Fortitude Family Office LLC now owns 94 shares of the medical instruments supplier's stock valued at $35,000 after buying an additional 66 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in Waters by 129.3% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 94 shares of the medical instruments supplier's stock valued at $35,000 after buying an additional 53 shares in the last quarter. Finally, Murphy & Mullick Capital Management Corp acquired a new position in Waters during the fourth quarter worth about $42,000. 94.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Baird R W upgraded shares of Waters from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, March 26th. StockNews.com cut shares of Waters from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th. Bank of America decreased their price target on shares of Waters from $430.00 to $410.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Robert W. Baird cut their price objective on Waters from $407.00 to $355.00 and set an "outperform" rating for the company in a research report on Tuesday. Finally, KeyCorp upgraded Waters from a "sector weight" rating to an "overweight" rating and set a $460.00 target price on the stock in a report on Monday, March 31st. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Waters presently has an average rating of "Moderate Buy" and an average target price of $392.13.

Waters Trading Up 4.8 %

Waters stock opened at $331.27 on Wednesday. Waters Co. has a 12 month low of $279.24 and a 12 month high of $423.56. The company has a quick ratio of 0.65, a current ratio of 0.94 and a debt-to-equity ratio of 1.14. The stock has a market cap of $19.71 billion, a P/E ratio of 30.93, a P/E/G ratio of 3.79 and a beta of 1.04. The company's fifty day simple moving average is $358.01 and its 200-day simple moving average is $370.81.

Waters (NYSE:WAT - Get Free Report) last issued its earnings results on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share for the quarter, topping the consensus estimate of $4.02 by $0.08. Waters had a return on equity of 46.31% and a net margin of 21.56%. As a group, sell-side analysts forecast that Waters Co. will post 12.86 EPS for the current fiscal year.

Waters Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.